troglitazone and Hepatitis studies

troglitazone and Hepatitis

troglitazone has been researched along with Hepatitis in 4 studies

Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.

Hepatitis: INFLAMMATION of the LIVER.

Research Excerpts

Excerpt	Relevance	Reference
"Troglitazone has been reported to be beneficial in a small group of patients with nonalcoholic steatohepatitis (NASH)."	5.31	Severe cholestatic hepatitis from troglitazone in a patient with nonalcoholic steatohepatitis and diabetes mellitus. ( Angulo, P; Lindor, KD, 2001)
"Troglitazone has been reported to be beneficial in a small group of patients with nonalcoholic steatohepatitis (NASH)."	1.31	Severe cholestatic hepatitis from troglitazone in a patient with nonalcoholic steatohepatitis and diabetes mellitus. ( Angulo, P; Lindor, KD, 2001)

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (25.00)	18.2507
2000's	3 (75.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Timeframe

Studies, this research(%)

All Research%

pre-1990

0 (0.00)

18.7374

1990's

1 (25.00)

18.2507

2000's

3 (75.00)

29.6817

2010's

0 (0.00)

24.3611

2020's

0 (0.00)

2.80

Authors

Authors	Studies
Krentz, AJ	1
Marra, F	1
Efsen, E	1
Romanelli, RG	1
Caligiuri, A	1
Pastacaldi, S	1
Batignani, G	1
Bonacchi, A	1
Caporale, R	1
Laffi, G	1
Pinzani, M	1
Gentilini, P	1
Maher, J	1
Angulo, P	1
Lindor, KD	1

Studies

Krentz, AJ

Marra, F

Efsen, E

Romanelli, RG

Caligiuri, A

Pastacaldi, S

Batignani, G

Bonacchi, A

Caporale, R

Laffi, G

Pinzani, M

Gentilini, P

Maher, J

Angulo, P

Lindor, KD

Other Studies

4 other studies available for troglitazone and Hepatitis

Article	Year
Non-alcoholic steatohepatitis. Lancet (London, England), 1999, Oct-09, Volume: 354, Issue:9186 Topics: Chromans; Contraindications; Diabetes Mellitus, Type 2; Fatty Liver; Hepatitis; Humans; Hypoglycemic	1999
Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology, 2000, Volume: 119, Issue:2 Topics: Antineoplastic Agents; Biological Transport; Cell Division; Cell Movement; Cell Survival; Cells, Cul	2000
Antidiabetic treatment for NASH? Hepatology (Baltimore, Md.), 2001, Volume: 33, Issue:5 Topics: Animals; CCAAT-Enhancer-Binding Proteins; Chromans; Diabetes Mellitus; DNA-Binding Proteins; Fatty L	2001
Severe cholestatic hepatitis from troglitazone in a patient with nonalcoholic steatohepatitis and diabetes mellitus. The American journal of gastroenterology, 2001, Volume: 96, Issue:5 Topics: Adult; Chemical and Drug Induced Liver Injury; Cholestasis; Chromans; Diabetes Mellitus, Type 1; Fat	2001

Article

Year

Non-alcoholic steatohepatitis.

Lancet (London, England), 1999, Oct-09, Volume: 354, Issue:9186

Topics: Chromans; Contraindications; Diabetes Mellitus, Type 2; Fatty Liver; Hepatitis; Humans; Hypoglycemic

1999

Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells.

Gastroenterology, 2000, Volume: 119, Issue:2

Topics: Antineoplastic Agents; Biological Transport; Cell Division; Cell Movement; Cell Survival; Cells, Cul

2000

Antidiabetic treatment for NASH?

Hepatology (Baltimore, Md.), 2001, Volume: 33, Issue:5

Topics: Animals; CCAAT-Enhancer-Binding Proteins; Chromans; Diabetes Mellitus; DNA-Binding Proteins; Fatty L

2001

Severe cholestatic hepatitis from troglitazone in a patient with nonalcoholic steatohepatitis and diabetes mellitus.

The American journal of gastroenterology, 2001, Volume: 96, Issue:5

Topics: Adult; Chemical and Drug Induced Liver Injury; Cholestasis; Chromans; Diabetes Mellitus, Type 1; Fat

2001